(FM) Inmunología
Departamento académico
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (5)
2024
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3
2017
-
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
Clinical Cancer Research, Vol. 23, Núm. 8, pp. 1929-1936
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97
2014
-
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
Journal of Translational Medicine, Vol. 12, Núm. 1
2011
-
Defining the critical hurdles in cancer immunotherapy
Journal of Translational Medicine